Bacterial and Fungal Microbiota of Patients With Severe Viral Pneumonia With COVID-19

University Hospital, Lille34 enrolled

Overview

Observational pilot single-center study aiming to determine the microbiota of critically ill patients infected with SARS-CoV-2. COVID-19 patients will be compared to historical critically ill controls with no SARS-CoV-2 infection. Respiratory and fecal microbiota (microbial and fungal) will be determined in COVID-19 patients on bronchoalveolar lavage and rectal swab. Inflammatory biomarkers will also be measured in COVID-19 patients. Characteristics of study patients will be collected at ICU admission and during ICU stay.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Sars-CoV2

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: For the Covid-19 Group: with a confirmed severe lung infection with CoV2-SARS-Cov2 admitted to the ICU. For the Control Group: * Historic cohort of non SARS -CoV2-infected adults admitted to the ICU (between March and October 2019), * that was investigated for fecal microbiota in a previous study (control patients in a fecal microbiota study in patients included in the SEAT study). Exclusion Criteria: * For the Covid-19 group: * Lack of coverage Patients who received antibiotic therapy within 6 weeks prior to Covid-19 symptomatology, * Pregnant women, * Severe immunosuppression: Neutropenia \< 0.5 G/L, Chemotherapy \< 6 months, Bone marrow transplant recipients, HIV with CD4+ lymphocytes \< 0.4 G/L * Impossible to perform bronchoalveolar lavage, * Non-socially insured, * Refusal to participate in the social study

Locations (1)

Hôpital Roger Salengro, CHU Lille

Lille, France

Outcomes

Primary Outcomes

Composition of the fecal bacterial and fungal microbiota

relative abundances and diversity indices

Time frame: At 28 days

Secondary Outcomes

Analysis of the faecal microbiota from rectal swab

Alterations in fecal microbiota composition (including virose, bacteria and fungi) in COVID-19 patients compared with controls

Time frame: at baseline and every 7 days during 28 days

Analysis of the respiratory microbiota from the bronchoalveolar lavage liquid

Alterations in respiratory microbiota composition (including virose, bacteria and fungi) in COVID-19 patients compared with controls

Time frame: at baseline and every 7 days during 28 days

Serum inflammatory markers changes

Changes in blood, c-reactive protein, leucocyte, lymphocyte from baseline

Time frame: at 28 days,

Inflammatory markers changes

changes in Cytokine/ chemokine from baseline

Time frame: at 28 days,

Mortality

death

Time frame: at 28 days,

mechanical ventilation free days

Number of days alive without mechanical ventilation

Time frame: at 28 days,

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.